Insider Trading March 7, 2026

Henry Schein Director Disposes of $228K in Stock Amid Mixed Market Signals

Director Laskawy sold 2,844 shares on March 5, 2026; company recently posted Q4 2025 results that beat consensus

By Leila Farooq HSIC
Henry Schein Director Disposes of $228K in Stock Amid Mixed Market Signals
HSIC

Henry Schein Inc. director Laskawy Philip A sold 2,844 shares on March 5, 2026 for $80.36 per share, a transaction worth $228,543. The sale occurred while the stock traded at $77.60 and after the company reported fourth-quarter 2025 results that exceeded earnings and revenue forecasts. Market valuation metrics cited in available research suggest the stock is above a calculated fair value.

Key Points

  • Director Laskawy Philip A sold 2,844 Henry Schein shares on March 5, 2026, for $80.36 each, totaling $228,543.
  • After the sale, Laskawy directly owns 21,961 shares.
  • Henry Schein beat fourth-quarter 2025 estimates with EPS of $1.34 and revenue of $3.4 billion; InvestingPro analysis lists a Fair Value of $71.33 and records a market value of $8.9 billion with a P/E of 23.93.

Summary: Director Laskawy Philip A of Henry Schein Inc sold 2,844 shares of company stock on March 5, 2026, at $80.36 per share, producing a total proceeds figure of $228,543. The sale coincides with a share price near $77.60 and comes after the company reported quarterly results that beat analysts' expectations.


Insider transaction details

According to a Form 4 filing with the Securities and Exchange Commission, Laskawy executed the sale on March 5, 2026. The filing records 2,844 shares disposed of at a transaction price of $80.36 each, totaling $228,543. After this disposition, the filing indicates Laskawy directly holds 21,961 shares of Henry Schein Inc.


Market context and valuation

At the time of the report, Henry Schein shares were trading at $77.60, a level noted as nearly 6% lower over the preceding week. An InvestingPro analysis cited alongside the filing places a Fair Value for the company at $71.33, suggesting the stock is trading above that calculated baseline. Additional valuation metrics included a market value of $8.9 billion and a price-to-earnings ratio of 23.93.


Recent financial performance

Henry Schein reported fourth-quarter results for 2025 that surpassed consensus estimates. The company's earnings per share for the quarter came in at $1.34 versus a forecast of $1.30. Quarterly revenue reached $3.4 billion, exceeding the $3.34 billion forecast. The announcement of these results was followed by an uptick in the company’s stock during pre-market trading. The filing notes analysts had forecasted the earnings figures and that the company outperformed those projections.


Services referenced

The materials accompanying the filing reference InvestingPro offerings, noting an array of additional tips and Pro Research Reports available for HSIC and other U.S. stocks. The filing’s valuation and market data derive from the InvestingPro analysis cited.


What is clear

The facts recorded in the regulatory filing and the company results are straightforward: a director sold a defined number of shares on a specific date and retains a stated remaining stake; the company reported quarterly figures that exceeded forecasts; and third-party analysis provided a fair value estimate and valuation metrics.

Risks

  • Short-term share-price fluctuation: the stock was trading at $77.60 and had declined nearly 6% over the prior week, indicating potential near-term volatility in the equity markets impacted by investor reactions.
  • Valuation gap: InvestingPro's Fair Value of $71.33 is below the trading level cited, presenting a risk that market price may correct toward the valuation estimate.
  • Reliance on analyst expectations: while the company outperformed forecasts for the quarter, future results remain subject to analysts' projections and market reactions that may affect the healthcare services sector and related equity valuations.

More from Insider Trading

Lamar Advertising CFO Disposes $173,325 in Stock Ahead of Quarter-End Mar 7, 2026 PepGen CEO Sells 5,275 Shares to Cover Tax Withholding; Market Reacts to Clinical Hold Mar 7, 2026 Five9 EVP Disposes $194,526 of Stock Under 10b5-1 Plan; Company Reports Q4 Beat and CEO Transition Mar 7, 2026 Motorola Solutions CEO Disposes $13.5M in Stock, Exercises Options for Equivalent Shares Mar 7, 2026 Orthofix CP&BOO Vitale Lucas Sells 2,312 Shares to Cover RSU Taxes Mar 7, 2026